Population Exposure–Response Analysis of the Effect of Ritlecitinib on Eyebrow and Eyelash Assessment in Patients with Alopecia Areata

    January 2025 in “ CPT Pharmacometrics & Systems Pharmacology ”
    Yuchen Wang, Yeamin Huh, Alexandre Lejeune
    Studysummary In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 9

    1. Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm Clinical Pharmacokinetics · 2024
    2. Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development Clinical Pharmacokinetics · 2023
    3. Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata Journal of The American Academy of Dermatology · 2023
    4. Concurrent Improvement in Scalp Hair and Eyebrow or Eyelash Regrowth in Patients With Severe Alopecia Areata Treated With Baricitinib Journal of The American Academy of Dermatology · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2 Journal of The American Academy of Dermatology · 2022
    7. Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss Journal of The American Academy of Dermatology · 2022
    8. Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism The Journal of Allergy and Clinical Immunology · 2015
    9. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015

    Related research 2

    1. Eyebrow and Eyelash Alopecia: A Clinical Review American journal of clinical dermatology · 2022
    2. A Technique for Reconstruction of Eyebrows and Eyelashes Seminars in Plastic Surgery · 2005